Drawing for THERAVECTYS

USPTO serial 79427841

THERAVECTYS

Reviewed by CopyMark Law Group

Reg. 8182382Status 700Registered
Filing date
Status date
Registration date
Mar 24, 2026
Examiner
DAVIS, MARC STEPHEN
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with THERAVECTYS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joseph Sofer

Joseph Sofer Ipsilon USA, LLP110 West 40th street, Suite 2001New York, NY 10128United States

Goods and services

ClassDescriptionStatusFirst use
001Chemical preparations for use in industry and science; chemical preparations for scientific use, other than for medical or veterinary use; biological preparations for use in industry and science; chemical reagents other than for medical or veterinary use; chemical preparations for analyses in laboratories other than for medical or veterinary use; diagnostic preparations other than for medical or veterinary use; lentiviral vectors for scientific research.ACTIVE—
005Pharmaceutical and veterinary preparations for the treatment of cancer, infectious diseases and emerging infectious diseases; vaccines; pharmaceutical preparations containing lentiviral vectors for medical, pharmaceutical and veterinary use, particularly for the treatment of cancer, infectious diseases and emerging infectious diseases; chemical, biological and pharmaceutical preparations for therapeutic, medical, pharmaceutical and veterinary use, particularly for the treatment of cancer, infectious diseases and emerging infectious diseases; diagnostic preparations for therapeutic, medical and veterinary use; chemical reagents for medical or veterinary use.ACTIVE—
040Pharmaceutical product custom manufacturing to order for third parties; vaccine manufacturing services to order for third parties.ACTIVE—
042Scientific research for medical purposes; research and development services for pharmaceutical preparations; conducting clinical trials in the nature of scientific research; clinical research for scientific purposes; conducting scientific feasibility studies and analyses; biological, biotechnological, biochemical, medical and pharmaceutical research and development services for third parties; evaluation of the efficacy of pharmaceutical products.ACTIVE—
044Medical analysis and medical diagnosis services for the treatment of cancer, infectious diseases and emerging infectious diseases; medical analyses of blood samples; medical assistance services relating to medicine and health care; provision of medical information.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 12, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Sep 24, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 3, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 3, 2026FIMPFINAL DISPOSITION PROCESSED—
Jun 24, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 24, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Mar 24, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 3, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 3, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 28, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 8, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 8, 2026XAECEXAMINER'S AMENDMENT ENTERED—
Jan 8, 2026GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 8, 2026GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 8, 2026CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 6, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 6, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 6, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 11, 2025RFNTREFUSAL PROCESSED BY IB—
Nov 26, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Nov 26, 2025RFRRREFUSAL PROCESSED BY MPU—
Oct 10, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 9, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 28, 2025DOCKASSIGNED TO EXAMINER—
Jul 18, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 18, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 17, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance